The BCL2L10 antibody is a tool used to detect BCL2L10. a member of the BCL-2 protein family, which regulates apoptosis by modulating mitochondrial outer membrane permeabilization. BCL2L10 (also termed BCL-B or BCLA) is an anti-apoptotic protein containing conserved BCL-2 homology (BH) domains. Unlike other BCL-2 family members, BCL2L10 exhibits tissue-specific expression, with higher levels observed in reproductive tissues, neurons, and certain cancer cells. It binds pro-apoptotic proteins like BAX and BAK, inhibiting their activity and promoting cell survival. Dysregulation of BCL2L10 is linked to cancer progression, chemoresistance, and poor prognosis, making it a potential therapeutic target. Antibodies against BCL2L10 are essential for studying its expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and flow cytometry. They also aid in exploring its role in diseases and evaluating inhibitors designed to block its anti-apoptotic function. Research utilizing these antibodies has provided insights into cellular survival mechanisms and strategies to overcome treatment resistance in malignancies.